Discover cutting-edge studies on carcinogenesis, biomarkers, and targeted therapeutic approaches
Explore the discovery of AZD0364, a potent ERK1/2 inhibitor showing promise in treating resistant non-small cell lung cancer through targeted molecular therapy.